Rigel Pharmaceuticals, Inc. (RIGL)
NASDAQ: RIGL · Real-Time Price · USD
22.60
+0.11 (0.49%)
Jan 30, 2025, 4:00 PM EST - Market closed
Rigel Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for RIGL stock have an average target of 34.8, with a low estimate of 20 and a high estimate of 57. The average target predicts an increase of 53.98% from the current stock price of 22.60.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for RIGL stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 | Jan '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +152.21% | Jan 23, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +152.21% | Jan 14, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Hold Maintains $15 → $25 | Hold | Maintains | $15 → $25 | +10.62% | Dec 10, 2024 |
| B. Riley Securities | B. Riley Securities | Hold Maintains $27 → $20 | Hold | Maintains | $27 → $20 | -11.50% | Dec 10, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $57 | Strong Buy | Reiterates | $57 | +152.21% | Dec 10, 2024 |
Financial Forecast
Revenue This Year
175.23M
from 115.78M
Increased by 51.34%
Revenue Next Year
202.83M
from 175.23M
Increased by 15.75%
EPS This Year
0.40
from -1.44
EPS Next Year
1.14
from 0.40
Increased by 187.62%
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 188.3M | 212.9M | 247.6M | |||
| Avg | 175.2M | 202.8M | 232.7M | |||
| Low | 162.9M | 190.1M | 211.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 62.6% | 21.5% | 22.1% | |||
| Avg | 51.3% | 15.8% | 14.7% | |||
| Low | 40.7% | 8.5% | 4.2% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 0.88 | 1.53 | 3.46 | |||
| Avg | 0.40 | 1.14 | 1.91 | |||
| Low | 0.09 | 0.52 | 0.77 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | 286.4% | 203.3% | |||
| Avg | - | 187.6% | 67.1% | |||
| Low | - | 30.9% | -32.2% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.